JP7762489B2 - ダントロレン製剤およびその使用方法 - Google Patents

ダントロレン製剤およびその使用方法

Info

Publication number
JP7762489B2
JP7762489B2 JP2020564888A JP2020564888A JP7762489B2 JP 7762489 B2 JP7762489 B2 JP 7762489B2 JP 2020564888 A JP2020564888 A JP 2020564888A JP 2020564888 A JP2020564888 A JP 2020564888A JP 7762489 B2 JP7762489 B2 JP 7762489B2
Authority
JP
Japan
Prior art keywords
dantrolene
pharmaceutical composition
present disclosure
peg
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524855A (ja
JPWO2019226621A5 (https=
JP2021524855A5 (https=
Inventor
ウェスコット、チャールズ
コグラン、ジル
Original Assignee
イーグル ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーグル ファーマスーティカルズ、インク． filed Critical イーグル ファーマスーティカルズ、インク．
Publication of JP2021524855A publication Critical patent/JP2021524855A/ja
Publication of JPWO2019226621A5 publication Critical patent/JPWO2019226621A5/ja
Publication of JP2021524855A5 publication Critical patent/JP2021524855A5/ja
Priority to JP2023191895A priority Critical patent/JP2024023270A/ja
Application granted granted Critical
Publication of JP7762489B2 publication Critical patent/JP7762489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020564888A 2018-05-21 2019-05-21 ダントロレン製剤およびその使用方法 Active JP7762489B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191895A JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
US62/674,394 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191895A Division JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Publications (4)

Publication Number Publication Date
JP2021524855A JP2021524855A (ja) 2021-09-16
JPWO2019226621A5 JPWO2019226621A5 (https=) 2022-05-25
JP2021524855A5 JP2021524855A5 (https=) 2022-05-25
JP7762489B2 true JP7762489B2 (ja) 2025-10-30

Family

ID=66821419

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564888A Active JP7762489B2 (ja) 2018-05-21 2019-05-21 ダントロレン製剤およびその使用方法
JP2023191895A Pending JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191895A Pending JP2024023270A (ja) 2018-05-21 2023-11-10 ダントロレン製剤およびその使用方法

Country Status (15)

Country Link
US (1) US20210236467A1 (https=)
EP (1) EP3796889A1 (https=)
JP (2) JP7762489B2 (https=)
KR (1) KR20210011961A (https=)
CN (1) CN112135605A (https=)
AU (1) AU2019272577B2 (https=)
BR (1) BR112020023012A2 (https=)
CA (1) CA3101093A1 (https=)
IL (1) IL278575B1 (https=)
MA (1) MA52707A (https=)
MX (2) MX2020012464A (https=)
SG (1) SG11202011121UA (https=)
UA (1) UA127661C2 (https=)
WO (1) WO2019226621A1 (https=)
ZA (1) ZA202006986B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017710A1 (fr) 1992-03-10 1993-09-16 Yamanouchi Pharmaceutical Co., Ltd. Preparation pharmaceutique pour administration transcutanee
JP2007525439A (ja) 2003-03-04 2007-09-06 リオトロピック セラピュティックス アイエヌシー． ダントロレンを用いる治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017710A1 (fr) 1992-03-10 1993-09-16 Yamanouchi Pharmaceutical Co., Ltd. Preparation pharmaceutique pour administration transcutanee
JP2007525439A (ja) 2003-03-04 2007-09-06 リオトロピック セラピュティックス アイエヌシー． ダントロレンを用いる治療

Also Published As

Publication number Publication date
AU2019272577B2 (en) 2024-08-08
MA52707A (fr) 2021-03-31
JP2021524855A (ja) 2021-09-16
CN112135605A (zh) 2020-12-25
ZA202006986B (en) 2024-04-24
MX2025002392A (es) 2025-04-02
IL278575A (https=) 2021-01-31
IL278575B1 (en) 2026-03-01
UA127661C2 (uk) 2023-11-22
JP2024023270A (ja) 2024-02-21
CA3101093A1 (en) 2019-11-28
SG11202011121UA (en) 2020-12-30
AU2019272577A1 (en) 2020-11-26
BR112020023012A2 (pt) 2021-02-02
KR20210011961A (ko) 2021-02-02
MX2020012464A (es) 2021-02-09
EP3796889A1 (en) 2021-03-31
WO2019226621A1 (en) 2019-11-28
US20210236467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US11738028B2 (en) Therapeutic regimen
US12186427B2 (en) Fulvestrant formulations and methods of their use
WO2012085185A1 (en) Aqueous solution of ambroxol
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
JP7762489B2 (ja) ダントロレン製剤およびその使用方法
ES2936832T3 (es) Formulaciones farmacéuticas de linagliptina
WO2013108180A1 (en) Aqueous paracetamol composition for injection
US9801859B2 (en) Bendamustine formulations
US8178489B2 (en) Formulation for aviptadil
RU2809143C2 (ru) Композиции дантролена и способы их применения
US20250018064A1 (en) Indocyanine compound-containing solid pharmaceutical composition
WO2024003338A1 (en) Annexin a1 liquid pharmaceutical composition
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
CA3215362A1 (en) Tetrodotoxin liquid formulations
CN117257936B (zh) 一种阿达木单抗组合物
US20200360284A1 (en) Fulvestrant formulations and methods of their use
US20250064758A1 (en) Antivirals targeting phosphatidic acid phosphatase (pap)
US20240180935A1 (en) Solution formulation of cyclophosphamide
US11826466B2 (en) Bendamustine solution formulations
EP4360622A1 (en) Ketorolac liquid composition, preparation method therefor, and application thereof
RU2791466C2 (ru) Схема лечения 2-амино-1-(2-(4-фторфенил)-3-(4-фторфениламино)-8,8-диметил-5,6-дигидроимидазо[1,2-а]пиразин-7(8н)-ил)этаноном и его комбинациями
WO2022034545A1 (en) Etelcalcetide formulations for parenteral use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231120

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251018

R150 Certificate of patent or registration of utility model

Ref document number: 7762489

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150